MedTrace Logo

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout

NCT05925166 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-04-15

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy and safety of Recombinant Human Tumor necrosis Factor-α Receptor Ⅱ Fusion Protein （rhTNFR-Fc）in the treatment of patients with acute Gout.

Conditions

  • Acute Gout

Interventions

DRUG

rhTNFR-Fc

Subjects will receive a dose of 25mg twice in 5 days(day 1 and the day 3).

DRUG

methylprednisolone

Subjects will be administered methylprednisolone 20 mg intravenous.

Sponsors & Collaborators

  • Lihua Duan

    lead OTHER

Principal Investigators

  • Lihua Duan, MD · Jiangxi Provincial People's Hopital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2025-07-01
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05925166 on ClinicalTrials.gov